Skip to main content

Clinical Prior Authorization Update for VMAT2 Inhibitors Scheduled for September 21, 2020

Last updated on 7/24/2020

Information posted July 24, 2020

The Vendor Drug Program (VDP) routinely updates existing clinical prior authorization criteria to reflect recent U.S. Food and Drug Administration (FDA)-approved indications or safety information from the product package insert, and will revise the Austedo (deutetrabenazine) criteria within the Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors clinical prior authorization on August 24, 2020:

  • Austedo is indicated for the treatment of tardive dyskinesia and Huntington-induced chorea. Current criteria require prescribing by, or its use overseen by, a neurologist or psychiatrist.
  • Revised criteria will remove the specialist requirement for only the treatment of tardive dyskinesia.

There will not be a change for the treatment of Huntington-induced chorea due to an increased risk of suicidality or suicidal ideation associated with Huntington disease.

Refer to page 4 of the criteria guide for more information.

This prior authorization is optional for Medicaid managed care. The Pharmacy Clinical Prior Authorization Assistance Chart shows the prior authorization that each managed care organization (MCO) uses and how they relate to the authorizations used for traditional Medicaid claims processing. This chart is updated quarterly and will be revised again in November. Providers can also refer to the VDP MCO Resources for links to each MCO's clinical prior authorizations.

Contact with comments or any questions.